Analysis: After Roche merger, biotech tail wags big pharma dog

ZURICH (Reuters) - When Roche paid $46.8 billion in 2009 to gain full ownership of Genentech, fears were rife that the arrival of the Swiss men in suits would stifle the free-wheeling innovative cultu…
Read the full story: Reuters: Health News